| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/JCP.0B013E318184FF5B |
| P698 | PubMed publication ID | 18794654 |
| P50 | author | Dan J. Stein | Q5213742 |
| P2093 | author name string | Christian de Bodinat | |
| Antti A Ahokas | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| generalized anxiety disorder | Q845224 | ||
| P304 | page(s) | 561-566 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Journal of Clinical Psychopharmacology | Q6294969 |
| P1476 | title | Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study | |
| P478 | volume | 28 |
| Q30462731 | 5-HT2C receptors in the basolateral amygdala and dorsal striatum are a novel target for the anxiolytic and antidepressant effects of exercise |
| Q30460367 | 5-hydroxytryptamine 2C receptors in the dorsal striatum mediate stress-induced interference with negatively reinforced instrumental escape behavior |
| Q28297569 | 50 years of hurdles and hope in anxiolytic drug discovery |
| Q34207131 | A benefit-risk assessment of agomelatine in the treatment of major depression |
| Q35749151 | A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities |
| Q22305782 | A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation |
| Q21285010 | Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report |
| Q28651498 | Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression |
| Q49111834 | Agomelatine facilitates positive versus negative affective processing in healthy volunteer models |
| Q38668480 | Agomelatine for the treatment of generalized anxiety disorder |
| Q37931969 | Agomelatine for the treatment of major depressive disorder |
| Q28274600 | Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness |
| Q43134466 | Agomelatine in the treatment of mood and anxiety disorders |
| Q38207149 | Agomelatine in treating generalized anxiety disorder |
| Q28686885 | Agomelatine in unipolar depression in clinical practice: a retrospective chart review |
| Q37598264 | Agomelatine, a melatonin agonist with antidepressant properties |
| Q34122643 | Agomelatine, the first melatonergic antidepressant: discovery, characterization and development |
| Q35628386 | Agomelatine: a novel antidepressant |
| Q38025987 | Anxiety and fear-avoidance in musculoskeletal pain. |
| Q57476908 | Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review |
| Q27009995 | Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders |
| Q38876395 | Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients |
| Q28764080 | Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults |
| Q28246147 | Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal |
| Q28287875 | Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression |
| Q28083141 | Emerging drugs for the treatment of anxiety |
| Q53091817 | Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. |
| Q38125645 | Fibromyalgia comorbid with anxiety disorders and depression: combined medical and psychological treatment |
| Q28292468 | Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data |
| Q48074026 | Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case |
| Q64090510 | Molecular basis for the association between depression and circadian rhythm |
| Q38869219 | Neuroendocrine Regulation of Anxiety: Beyond the Hypothalamic-Pituitary-Adrenal Axis |
| Q47569133 | Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders |
| Q38071131 | New approaches to the pharmacological management of generalized anxiety disorder. |
| Q38238790 | New insights on the antidepressant discontinuation syndrome. |
| Q94958342 | Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations |
| Q38203356 | Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder |
| Q34484276 | Pharmacological treatment for generalized anxiety disorder in adults: an update |
| Q59410448 | Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review |
| Q35686859 | Pharmacotherapy of anxiety disorders: a critical review |
| Q26864049 | Profile of agomelatine and its potential in the treatment of generalized anxiety disorder |
| Q63433272 | Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials |
| Q37776074 | Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission |
| Q38033191 | Role of melatonin in mood disorders and the antidepressant effects of agomelatine |
| Q48125393 | Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration |
| Q46904550 | Studies into the anxiolytic actions of agomelatine in social isolation reared rats: Role of corticosterone and sex. |
| Q36837462 | The diagnosis and treatment of generalized anxiety disorder |
| Q47920437 | The effects of antidepressant treatment in prenatally stressed rats support the glutamatergic hypothesis of stress-related disorders. |
| Q62373349 | The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors |
| Q26781117 | The overlap between anxiety, depression, and obsessive-compulsive disorder |
| Q37809108 | The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential |
| Q36917104 | The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders |
| Q41535764 | Treatment of anxiety disorders |
Search more.